Co-Founder, President and Chief Executive Officer
An experienced life science venture capitalist and company executive, Klausner was previously CEO and a board member of Gem Pharmaceuticals (non-cardiotoxic doxorubicin analog vs. cancer that was acquired by Monopar Therapeutics in 2017), and CEO and a board member of Jade Therapeutics (ophthalmic applications of a cross-linked hyaluronic acid polymer that was acquired by EyeGate Pharmaceuticals in 2016). Prior to his operating roles, Klausner spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. During that time, he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. He currently serves on the Board of Directors of Monopar Therapeutics, and on the Life Sciences Investment Review Board for the New York University Innovation Venture Fund. Mr. Klausner earned his M.B.A. from the Stanford University School of Business and his B.A. in Biology from Princeton University.